This Presidential Proclamation directs adjustments to the importation of patented pharmaceuticals and associated active pharmaceutical ingredients (APIs) based on a finding that current import levels threaten national security by creating overreliance on foreign supply chains for critical medications.

The President imposes a 100% ad valorem tariff on these imports, while simultaneously offering reduced rates (20% or 0%) to companies that commit to or achieve onshoring of production and pricing agreements, and grants zero tariffs to certain specialized pharmaceutical categories.

The action also directs federal departments to pursue negotiation agreements to further secure domestic supply and requires monitoring of generic drug imports, though no immediate tariffs are placed on generics.

This Presidential Proclamation modifies and strengthens existing Section 232 tariff regimes on imports of aluminum, steel, and copper, building upon prior actions established in Proclamations 9704, 9705, and 10962.

The President determined that the tariffs are effectively strengthening domestic industries, but further adjustments are necessary to address identified national security threats more completely.

Key modifications include applying the additional *ad valorem* duties to the full customs value of imported articles and their derivatives, regardless of the percentage of metal content, while setting new specific tariff rates (50% or 25%) for certain articles and granting reduced rates for products sourced from the United Kingdom or made entirely from U.S. metals.

The proclamation also terminates prior inclusion processes for derivative articles, authorizing the Secretary of Commerce and the Trade Representative to jointly determine future inclusions.